Tirzepatide vs Semaglutide: What the Clinical Trials Actually Show

For a few years, comparing tirzepatide and semaglutide for weight loss meant comparing separate trials — different populations, different durations, different placebo groups. That made head-to-head claims murky.

That changed in May 2025 when the SURMOUNT-5 trial published in the New England Journal of Medicine — the first randomized, direct comparison of the two agents in people with obesity. The results gave researchers a cleaner answer than indirect comparisons ever could.

Here’s what the evidence actually shows.

Two Different Mechanisms

Semaglutide is a GLP-1 receptor agonist — it mimics glucagon-like peptide-1, a gut hormone that suppresses appetite, slows gastric emptying, and improves glucose regulation. It’s the mechanism behind Wegovy (weight management) and Ozempic (diabetes).

Tirzepatide goes one step further. It’s a dual agonist — it activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. GIP is a separate incretin hormone that plays a role in insulin secretion, insulin sensitivity, and adipose tissue metabolism. The working hypothesis is that activating both pathways produces a greater metabolic effect than either alone.

This dual mechanism isn’t a branding distinction — it has measurable downstream consequences in the data.

The Landmark Trials: Separate Evidence

Before SURMOUNT-5 provided a head-to-head answer, the evidence base relied on two pivotal single-agent trials.

STEP-1 (semaglutide 2.4 mg, 2021): Adults with obesity or overweight but without diabetes received weekly semaglutide for 68 weeks. Mean body weight reduction was 14.9% versus 2.4% with placebo. More than 86% of participants lost at least 5% of body weight; half lost 15% or more.

SURMOUNT-1 (tirzepatide, 2022): The same basic design — adults with obesity, no diabetes, 72 weeks. Results came in dose-dependent tiers: 15.0% weight loss at the 5 mg dose, 19.5% at 10 mg, and 20.9% at the maximum 15 mg dose, all versus 3.1% with placebo. At 15 mg, 57% of participants lost 20% or more of their body weight.

Cross-trial comparisons suggested tirzepatide had the edge, but without randomizing the same people to both treatments, those comparisons had real limitations. SURMOUNT-5 resolved that.

SURMOUNT-5: The Head-to-Head Data

Published in May 2025, SURMOUNT-5 enrolled 751 adults with obesity or overweight (without type 2 diabetes) and randomized them to either the maximum tolerated dose of tirzepatide (10 or 15 mg weekly) or the maximum tolerated dose of semaglutide (1.7 or 2.4 mg weekly) for 72 weeks.

The results were not close.

• Tirzepatide: mean weight reduction of 20.2% (approximately 22.8 kg / 50 lbs)
• Semaglutide: mean weight reduction of 13.7% (approximately 15.0 kg / 33 lbs)

The 6.5 percentage point difference was statistically significant (P < 0.001). Waist circumference also narrowed more with tirzepatide: −18.4 cm versus −13.0 cm.

Categorical thresholds showed the same pattern. Roughly 50% of tirzepatide participants lost 20% or more of their body weight versus about 27% with semaglutide. For the 25% threshold, the split was 32% versus 16%.

The safety profiles were broadly comparable — gastrointestinal side effects (nausea, diarrhea, constipation) were the most common adverse events in both groups, mostly mild to moderate and concentrated during dose escalation.

Body Composition: What Gets Lost?

A question that often gets lost in headline weight numbers is what is actually being lost. A 20% reduction in scale weight means very little if a large portion is lean tissue.

A DXA substudy from SURMOUNT-1 examined this directly. In participants with imaging data at baseline and week 72, tirzepatide produced a 33.9% reduction in fat mass and a 10.9% reduction in lean mass — a ratio of roughly 75% fat to 25% lean. That ratio was nearly identical to the placebo group, suggesting tirzepatide’s lean mass loss was proportional to the caloric deficit, not an artifact of the drug itself.

Visceral fat — the metabolically active fat stored around abdominal organs — declined by 40.1% in the tirzepatide group. That figure matters clinically: visceral adiposity is more closely linked to cardiovascular and metabolic disease risk than subcutaneous fat.

The usual guidance applies regardless of which therapy is used: adequate protein intake and resistance training during a significant weight-loss period help preserve muscle mass.

Real-World Data Confirms the Gap

A 2024 observational study in JAMA Internal Medicine examined matched cohorts of adults with overweight or obesity treated with either tirzepatide or semaglutide in routine clinical practice. At 12 months, tirzepatide users showed approximately 6.9 percentage points greater weight loss on treatment, with higher proportions achieving the 5%, 10%, and 15% thresholds.

Real-world populations include more comorbidities, variable adherence, and fewer lifestyle supports than trial participants — so the absolute numbers are lower for both drugs. But the relative advantage held.

Earlier Head-to-Head Data in Type 2 Diabetes

The SURPASS-2 trial (2021, NEJM) randomized adults with type 2 diabetes to tirzepatide at three doses or semaglutide 1 mg. At 40 weeks, weight reductions were 7.6 kg (5 mg), 9.3 kg (10 mg), and 11.2 kg (15 mg) with tirzepatide versus 5.7 kg with semaglutide 1 mg. The comparison wasn’t at the maximum semaglutide obesity dose (2.4 mg), but the directional finding aligned with what SURMOUNT-5 later confirmed.

What This Means for People Researching Options

For someone evaluating these therapies, the data now makes a clearer case than it did two years ago: in direct comparison, tirzepatide produced meaningfully greater average weight loss at maximum tolerated doses. Both agents significantly outperform placebo, and both carry similar GI tolerability considerations.

The clinically relevant question isn’t purely about which compound has the larger average trial number — it’s about individual fit. Dose escalation tolerance, cost, insurance coverage, access, and prescriber familiarity all factor into treatment selection. Some people achieve excellent results with semaglutide at doses they tolerate well. Others may benefit from the additional mechanism tirzepatide offers.

Both therapies are prescription medications prescribed for specific indications. Use the provider directory to find clinicians who specialize in peptide-based metabolic therapies, or explore the price index for current market pricing across vendors.

This article is for educational purposes only. It does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or modifying any medication or treatment protocol.